A method for the treatment of sensorineural hearing loss

 

(57) Abstract:

The invention relates to medicine, namely to otorhinolaryngology and can be used in the treatment of sensorineural hearing loss. The inventive spend three courses of treatment, with each ten-day course of daily affect 3-5 acupuncture points, taken from a number T14T20, PN13, PN14, PN15, PN16, PN21, PN63, PC11CJ4EX8EX9by the adoption of the drugs in the following sequence: first year using Cerebrolysin 0.1 ml on the second - Cavinton 0.1 ml, and the third - neostigmine 0.1 ml, which give, respectively, five, five and three acupuncture points. 2 C.p. f-crystals, 4 Il.

The invention relates to medicine, namely to otorhinolaryngology.

From the prior art known method of treatment of sensorineural hearing loss (pascar N. N. and other Reflexology and its use in patients with cochlear neuritis. Bulletin of otorhinolaryngology, 1993, No. 6, S. 21-24), including the impact on acupuncture points.

The disadvantage of this method is that it does not improve hearing.

Izvesti in patients with chronic cochlear neuritis. Journal of the ear, nose and throat diseases, 1987, No. 5, S. 55-57), including the impact on acupuncture points (TR5, TR17- TR22VB2VB12VB20VB21, JG3, JG4, JG19, GJ4, GJ11E36F2F3V11, T14) the outer and inner ear, neck, kidneys, Shen-men, cortex and brain stem will first carry out acupuncture at distant points General steps daily for 20 min, then within 2-3 min act on one point ahead of the ear, then on the second point, located behind the first, and 2-3 auricular points for 1 minutes Per session total number of stimulated points can be up to 10.

Treatment includes 10 daily sessions, and if necessary, repeat the course next month.

When using the known method in all (100%) patients noted improvement of speech intelligibility due to improvement in General condition, as well as the reduction or disappearance of subjective noise.

The disadvantage of this method is that it does not provide the increased level of hearing. In addition, the known method is characterized by greater duration is the basis of the invention tasked to develop a method for the treatment of sensorineural hearing loss, providing increased levels of hearing while reducing the duration of sessions of treatment.

The problem is solved by the fact that in the treatment for sensorineural hearing loss, including a daily impact on acupuncture points during a ten-day course of treatment interval, according to the invention spend three courses of treatment with an interval between them is equal to 7 to 8 days, during each ten-day course of daily affect 3-5 acupuncture points, taken from a number T14, T20, PN13, PN14, PN15, PN16, PN21, PN63, PC11, GJ4EX9and EX8by the adoption of the drugs in the following sequence: the first course of treatment is administered a drug that improves the metabolism in the brain tissue, the second extends the cerebral vessels, and the third with pronounced anticholinesterase activity.

Suitable as drugs, respectively courses to use Cerebrolysin 0.1 ml, Cavinton 0.1 ml and neostigmine 0.1 ml, which give respectively 5, 5 and 3 acupuncture points.

Profitable within three decetive.

The proposed method improves the efficiency of treatment with a new set of acupuncture points and double the impact on them. Indeed, on the one hand, the impact of a needle on acupuncture points creates an artificial element that switches itself a pathological impulses and contributes to the destruction of components of pathological reactions. As a result, conditions for the normalization of the functional state of the nervous system.

On the other hand, with the introduction of drugs into the active points of the power and duration of their effects increase several times. In addition, the proposed combination of drugs and the sequence of their introduction provide for gradual penetration in their circulatory system and then distribute them throughout the body such an impact on him, which not only improves the General condition of the patients, but increases them and the level of hearing. The duration of sessions is 3-5 min, which can significantly improve the throughput and to facilitate the treatment of children.

The invention is further illustrated by a description of specific examples of its implementation is its; in Fig. 2 acupuncture points located on the hand; Fig. 3 and 4 the audiogram.

The method is as follows.

Spend three ten-day course of treatment with the spacing between them is equal to 7-8 days. During each daily rate to the patient is injected with an insulin syringe drugs in 3-5 acupuncture points belonging to the following row:

T14(Yes Jui) injection of 0.5-1 cm vertically;

GJ4(he GU) injection of 0.5-1 cm vertically;

PN63(Shang how si) injection of 0.5 cm horizontally;

PN16(tin min) injection of 0.5 cm horizontally;

PN21(HOU Tsung) injection of 0.3-0.5 cm, injection slanting towards the nose;

T20(Bai Hui) subcutaneously, from front to back at an angle of 15o;

RS11(Shan lui) subcutaneously, horizontally;

PN13(ting Hsu) horizontally, subcutaneously;

PN14(tin Lin) horizontally, subcutaneously;

PN15(ting Tsung) horizontally, subcutaneously;

EX9(NP) (Anmian (II) subcutaneously, vertically;

EX8(NP) (Amnian I) subcutaneously, vertically.

The injection site pre-treated with alcohol.

For pharmacopuncture use the following drugs:

Cerebrolysin is th tissue.

Cavinton this ethyl ester apovincaminate acid it increases the cerebral blood vessels, increases blood flow, improves the supply of oxygen to the brain.

Neostigmine (m-Dimethylcarbamoyl) trimethylamine the methyl sulfate - has expressed anticholinesterase activity and causes the enhancement of neuromuscular conduction. The drug has a stimulating effect on the Central nervous system, in particular its cortical Department and secondary structure of the brain. Neostigmine significantly increases the hearing sensitivity.

First Cerebrolysin administered daily for 10 days. In each session using 5 active points, each point injected 0.1 ml of the drug. Thus, in one session, use 0.5 ml of the drug. Then a break for 7 days. Then enter Cavinton daily and also within 10 days. In one session using 5 points, each point injected 0.1 ml of the drug. Thus, in one session, use 0.5 ml of the drug. A break of 7 days. The daily for 10 days administered neostigmine, used by 3 points in a single session. At each point injected 0.1 ml of the drug. Thus, in one session, use 0.3 ml neostigmine methylsulfate.

Example 1. Patient E. Repin 12 years. Complaints: NAA sensorineural hearing loss II. From the anamnesis it is established that hearing problems have been since birth. At the age of 1 year 6 months was a concussion. The audiologist asked later, when there were serious problems with hearing. A survey was conducted: the tonal audiogram, RAS-study Nagornoye tests, the conclusion of the audiologist. The patient was administered Cerebrolysin in the following points:

1st day T20; T14; GJ4(left), EX8(2) (0.5 ml)

2nd day T20; PN16(2); PN15(2) (0.5 ml)

day 3 PN13(2); PN14(2); EX9(left) (0.5 ml)

4th day T20; EX8(2); PN21(2) (0.5 ml)

5 day T20; PN15; PN16(2) (0.5 ml)

day 6 T20; GJ4(left); PC11(2) (0.5 ml)

day 7 PN13(2); PN14(2); PN63(left) (0.5 ml)

8 day T20; EX8(2); EX9(2) (0.5 ml)

9th day PN13(2); PN14(2); PN63(left) (0.5 ml)

10th day T20; T14; EX8(2); GJ4(left) (0.5 ml)

7 days holiday

Further Cavinton:

1st day T20; T14; GJ4(left); PN21(2) - (0.5 ml)

2nd day T20; PC11(2); PN63(left); T14- (0.5 ml)

day 3 EX9(left); PN13(2); PN14(2) (the VA) (0.5 ml)

day 6 T20; EX8(2); PN2(2) (0.5 ml)

7-day T20; PN13(2); PN14(2) (0.5 ml)

8 day T20; PN15(2); PN16(2) (0.5 ml)

9th day T20; PC11(2); PN63(left); EX9(left) (0.5 ml)

10th day T20; PN15(2); PN16(2) (0.5 ml)

7 days break.

Further proserin:

1st day T20; PN21(2) (0.3 ml)

2nd day T20; EX8(2) (0.3 ml)

day 3 PN21(2); PN63(left) (0.3 ml)

4th day T20; PN15(2) (0.3 ml)

5 day T14; PC11(2) (0.3 ml)

day 6 T20; PN16(2) (0.3 ml)

day 7 EX9(2); GJ4(left) (0.3 ml)

8 day T20; PN13(2) (0.3 ml)

9th day EX8(2); PN63(left) (0.3 ml)

day 10 PN13(2); T20(0.3 ml)

The results of treatment are presented in Fig. 3, where curves 1 and 2 respectively according to lowering of the hearing on the right ear before and after treatment, and curves 3 and 4 respectively according to the decrease of hearing on the left ear before and after treatment.

After treatment srednedushevyh frequencies on the right ear changes amounted to 15 dB (from 55 to 40 dB), on the left ear 20 dB (65 dB to 45 dB).

Example 2. Patient A. Zaripov 6 years. Diagnosis: the TLD is . From the anamnesis: hearing problems since birth. The mother throughout pregnancy was threatened miscarriage, rapid delivery. The child was conducted medical, physiotherapeutic treatment effect was not. A survey was conducted: tone audiogram, speech audiometry, obtained the opinion of therapist.

Were treated:

The Cerebrolysin:

1st day T20; T14; GJ4(left); PN21(2) - (0.5 ml)

2nd day T20; PC11(2); PN63(left); T14- (0.5 ml)

day 3 EX9; PN13(2); PN14(2) (0.5 ml)

4th day T20; PN15(2); PN16(2) (0.5 ml)

day 5 PN13(2); PN14(2); PN63(left) (0.5 ml)

day 6 T20; EX8(2); PN21(2) (0.5 ml)

day 7 PN13(2); T20; PN14(2) (0.5 ml)

8 day T20; PN15(2); PN16(2) (0.5 ml)

9th day T20; PC11(2); PN63(left); EX9(left) (0.5 ml)

10th day T20; PN15(2); PN16(2) (0.5 ml)

7 days break.

Further Cavinton:

1st day T20; PC11(2); EX9(2) (0.5 ml)

day 2 PN13(2); PN14(2); T20(0.5 ml)

3rd day T20; EX8(2); GJ4(after the 11 (2); EX9(2) (0.5 ml)

day 6 T20; PN15(2); PN16(2) (0.5 ml)

day 7 PN13(2); PN14(2); T14(0.5 ml)

8 day T20; PC11(2); PN63(left); PN21(left) (0.5 ml)

9th day T20; GJ4(left); EX8(2) (0.5 ml)

day 10 PN13(2); PN14(2); T20(0.5 ml)

7 days break.

Further proserin:

1st day T20; PC11(2) (0.3 ml)

day 2 PN13(2); PN63(left) (0.3 ml)

3rd day T14; EX8(2) (0.3 ml)

day 4 PN16(2); GJ4(left) (0.3 ml)

5 day T20; EX9(2) (0.3 ml)

day 6 GJ4(left); PN15(2) (0.3 ml)

day 7 PN21(2); PN63(left) (0.3 ml)

8 day T20; PN14(2) (0.3 ml)

9th day T20; PC11(2) (0.3 ml)

10th day T20; PN16(2) (0.3 ml)

The results of treatment are presented in Fig. 4, where the curves 1 and 2 respectively according to lowering of the hearing on the right ear before and after treatment, and curves 3 and 4 respectively according to the decrease of hearing on the left ear before and after treatment.

After treatment in mid-speech frequencies in the right ear changes amounted to 18.5 dB (63,7 to 50.2 dB), and on the left of 11.5 dB (66.5 to 55 dB). Treatment what was the improvement in General condition, and in 62% of patients improved hearing more than 10 dB.

The method is not accompanied by addiction to drugs and the emergence of allergies due to the smallness of the injected dose. Treatment is possible on an outpatient basis.

1. A method for the treatment of sensorineural hearing loss, including a daily impact on acupuncture points during a ten-day course of treatment interval, wherein spend three treatment intervals between 7 to 8 days, during each ten-day course of daily affect 3 5 acupuncture points, taken from a number T14T20, PN14, PN15, PN16, PN21, PN63, PC11, GJ4EX8EX9by introducing them to drugs in the following sequence: in the first year introduce a drug that improves the metabolism in the brain tissue, the second extends the cerebral vessels, and the third with pronounced anticholinesterase activity.

2. The method according to p. 1, characterized in that in the first year using Cerebrolysin 0.1 ml on the second Cavinton 0.1 m is

3. The method according to p. 1, characterized in that during the three ten-day courses of treatment at each point acupuncture the above number to affect not less than three times.

 

Same patents:

The invention relates to medicine, namely to methods for preparations of brain tissue hydrolysates

The invention relates to medicine and can be used to obtain material for scleroplasty

The invention relates to medicine and relates to a method of obtaining biologically active substances from raw materials of animal origin with antiandrogenna and antiestrogenic activity
The invention relates to veterinary medicine and can be used for other biostimulating substances for the treatment, prophylaxis and immunotherapy in animals and humans, as well as for making balms, liniments, creams, lotions, etc
The invention relates to medicine, namely to the treatment of ulcer and 12 duodenal ulcer

The invention relates to medicine, namely to methods for treating disorders of coordination

The invention relates to the medical industry, in particular to a method for cholesterol used for the production of steroid hormones, vitamin D3and liquid-crystal derivatives

The invention relates to the medical industry, in particular to a method for cholesterol used for the production of steroid hormones, vitamin D3and liquid-crystal derivatives

The invention relates to compounds of the formula

(I)

where R1represents hydrogen, lower alkyl, lower alkenyl, lower quinil, aryl lower alkyl, cycloalkyl lower alkyl, lower alkoxy lower alkyl, hydroxy lower alkyl, amino lower alkyl, mono - or di-lower alkyl, amino lower alkyl, formyl, lower alkylsulphonyl, amino lower alkylsulphonyl, lower alkoxycarbonyl, mono - or di-aryl-substituted lower alkyl, arylcarbamoyl lower alkyl, aryloxy lower alkyl, or lower alkylene

< / BR>
X represents O or S;

W represents hydrogen, halogen, hydroxy, lower alkoxy, aryl lower alkoxy, nitro, trifluoromethyl or

< / BR>
where R3represents hydrogen, lower alkyl or aryl lower alkyl, and R4represents lower alkyl or aryl lower alkyl; or alternatively the groupas a whole represents the

< / BR>
R5is hydrogen, lower alkyl, aryl or aryl lower alkyl; and

Z predepression

Eye ointment // 2082434
The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment of traumatic keratitis, chemical burns, conjunctivitis, corneal, and especially when wound infection

The invention relates to new derivatives of diazepinone having valuable properties, in particular derivatives of diazepinone General formula (I)

< / BR>
where B is one of the divalent residues and) g)

< / BR>
and

X, l, m, n and R1R7have the following meanings:

X Gruppen or, if B denotes the divalent residue (a), a nitrogen atom,

l integer 1, 2 or 3,

m is an integer 1 or 2,

n is an integer of 1 to 4,

R1a hydrogen atom or an unbranched or branched alkyl with 1 to 6 carbon atoms,

R2a hydrogen atom, an unbranched or branched alkyl with 1 to 8 carbon atoms, unbranched or branched alkenyl with 4 to 6 carbon atoms, cycloalkyl with 3 to 7 carbon atoms, unsubstituted or substituted by alkyl with 1 to 3 carbon atoms, substituted, phenyl, unsubstituted or substituted by one or two methyl groups or methoxypropane or one halogen atom, or phenylalkyl with 1 to 3 carbon atoms in the alkyl part, unsubstituted or substituted at the fragrance stands or methoxy group or a halogen atom,

R3and R4the same or the difference is,

R5a hydrogen atom or a chlorine or methyl,

R6and R7the same or different and denote hydrogen atoms or alkali with 1 to 3 carbon atoms, and, in addition, R7may also indicate a halogen atom,

mixtures of their isomers or their individual isomers and their salts, mainly their physiologically tolerated acid additive salts, in particular with pharmacological action
The invention relates to medicine and veterinary medicine, namely to the new immune modulating drug on the basis of N-metrocable-9-acridone and physiologically active monosaccharides, various buildings

The invention relates to medicine, namely to the production of medicines on the basis of [N-methyl-N-/D-glyukopiranozil/ammonium-2-/acridin-9-one-10-Il/acetate] -cycloferon, and can be used for the treatment of acquired immunodeficiency syndromes (AIDS), including HIV-related

The invention relates to medicine, namely to the production of medicines on the basis of [N-methyl-N-/D-glyukopiranozil/ammonium-9-one-10-Il/acetate] -cycloferon, and can be used for the treatment of multiple sclerosis
The invention relates to veterinary pharmacology, in particular to methods of treatment of acute respiratory infections in young farm animals

The invention relates to methods for enhancing the effectiveness of small doses of medicines for various purposes, in particular hypnotic, analgesic, sedative and narcotic drugs, and can be used in medicine with the aim of saving drugs and to reduce their toxicity and side effects
Up!